PAVmed Inc. — Q2 2016 Form 10-Q
Business context and reporting period. Unaudited results cover the quarter and six months ended June 30, 2016. PAVmed is an early-stage medical-device company developing products for commercialization; it had no product revenue. The company completed its IPO on April 28, 2016, selling 1,060,000 units at $5.00 each and receiving approximately $4.2 million in net proceeds. Common stock and warrants began trading separately on Nasdaq on July 27, 2016.
Key financial metrics
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $1.315 million | $361 thousand | $2.012 million | $507 thousand |
| Net loss | $1.315 million | $361 thousand | $2.012 million | $507 thousand |
| Basic and diluted loss per share | $0.10 | $0.03 | $0.16 | $0.05 |
| Net cash used in operating activities | Not separately stated | Not separately stated | $2.025 million | $284 thousand |
At June 30, cash was $3.023 million, working capital was $2.736 million, total assets were $3.153 million, and stockholders’ equity was $2.749 million. Current liabilities were $403 thousand; the balance sheet reports no debt. Cash increased from $767 thousand at December 31, 2015. Six-month investing cash use was $14 thousand; financing provided $4.295 million, principally from the IPO. No gross margin is applicable because the company reported no revenue.
Changes versus the prior comparable period
Q2 net loss rose to $1.315 million from $361 thousand; six-month net loss increased to $2.012 million from $507 thousand. For the first half, formation and operating costs increased 249% to $1.477 million, while research and development expense rose 540% to $534 thousand. Management attributed higher spending to broader product development, increased personnel and professional fees, public-company and IPO costs, office expenses, and newly recognized stock-based compensation. Operating cash use also increased substantially year over year.
Outlook, commentary, and risks
- Management expected losses to continue for several years and did not expect positive operating cash flow in the near future. It believed available cash would fund anticipated expenses and capital needs into early 2017, subject to assumptions that could prove incorrect; additional capital may be required, with potential dilution or debt restrictions.
- Pipeline milestones were developmental, not approvals: PortIO verification and validation was targeted for completion by year-end 2016 before FDA submission; CarpX and NextCath testing was expected to begin by year-end 2016, with submissions anticipated in 2017. Caldus development and testing continued; NextFlo design and intellectual-property work continued. Timelines and outcomes remain uncertain.
- Key risks include product development and regulatory clearance, market acceptance and commercialization, intellectual-property protection, access to external engineering and manufacturing expertise, expense control, and the ability to raise capital. The filing states that failure to obtain sufficient funding or regulatory clearance could impair planned operations and the company’s ability to meet objectives.
- Unusual and potential dilution items: the IPO included one warrant per unit; 10.62 million warrants were outstanding at June 30, generally exercisable at $5.00 per share. The company also granted 1.588 million stock options at $5.00 per share; $2.846 million of related compensation cost remained unrecognized, expected over 2.8 years. These instruments were excluded from diluted loss per share as anti-dilutive.
- Related-party management services from an affiliate of a director cost $150 thousand in the first half. A five-year CMO employment agreement became effective July 1, 2016, with a $285 thousand annual base salary and a $50 thousand initial bonus accrued at June 30. The amended office lease had $153 thousand of future commitments. Management reported no pending legal action expected to have a material adverse effect.
Important facts for investors to verify
- Whether the disclosed cash runway into early 2017 remains achievable against actual operating cash burn and development spending.
- Progress, evidence, and timing for each product’s testing, FDA submissions, clearance, and eventual commercialization.
- Future financing needs and the potential dilution from outstanding warrants, options, and other equity instruments.
- Terms and ongoing costs of related-party services, executive compensation, and office commitments.
- The assumptions underlying product revenue projections and equity-based award valuations; the company had no revenue and acknowledged substantial execution and regulatory uncertainty.